Abstract | AIMS AND BACKGROUND: METHODS AND STUDY DESIGN: RESULTS: There were no statistically significant differences in gender, age, T stage, N stage, clinical staging and treatment method between the high ERCC1 expression and low ERCC1 expression groups. Fifty-eight patients (87.88%) had a complete response and 8 (12.12%) a partial response. Of the 34 patients with high ERCC1 expression, 10 (29.41%) relapsed, compared with 4 of 32 (12.5%) patients with low ERCC1 expression (P = 0.041). The 5-year overall survival rate was 58.82% in patients with high ERCC1 expression and 84.37% in patients with low ERCC1 expression (P = 0.022). Multivariate analysis showed that low expression of ERCC1 was a significant independent prognostic factor for better overall survival (P = 0.026). CONCLUSIONS:
|
Authors | Zhongxin Zhang, Changqing Jiang, Likuan Hu |
Journal | Tumori
(Tumori)
2014 May-Jun
Vol. 100
Issue 3
Pg. 328-32
ISSN: 2038-2529 [Electronic] United States |
PMID | 25076246
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Biomarkers, Tumor
- DNA-Binding Proteins
- ERCC1 protein, human
- Endonucleases
- Cisplatin
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Biomarkers, Tumor
(analysis)
- Chemoradiotherapy
- Cisplatin
(administration & dosage)
- DNA-Binding Proteins
(analysis)
- Down-Regulation
- Endonucleases
(analysis)
- Female
- Gene Expression Regulation, Neoplastic
- Humans
- Immunohistochemistry
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Nasopharyngeal Neoplasms
(mortality, pathology, therapy)
- Neoplasm Staging
- Predictive Value of Tests
- Treatment Outcome
|